フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW...
VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN...
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for...
Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory...
Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency...
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020...
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent...
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis...
#outlook a {padding:0;} body {width:100%; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; margin:0; padding:0;} .ReadMsgBody...
p{margin:10px 0;padding:0;}table{border-collapse:collapse;}h1,h2,h3,h4,h5,h6{display:block;margin:0;padding:0;}img,a...
Repurposing Drugs Reduces Investment Risk. Algernon Pharma Plans Phase 2 Trials for NASH, CKD and IBD Time to put down your...
MADISON HEIGHTS, Mich., Dec. 4 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today...
CHICAGO, Sept. 29 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for AAPL, AA, KMX, AGN, and ANN. Seven Summits Strategic...
Register on LATISSE(TM) Web Site to Help Reach Goal IRVINE, Calif., March 27 /PRNewswire-FirstCall/ -- Allergan, Inc. (NYSE: AGN) hosted a...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約